Skip to content
Hair Pipeline
← Back to the pipeline

BNZ-1

A peptide blocking three cytokines at once, including the one most implicated in alopecia areata.

Phase 2BiologicInjectableImmunomodulator

No public activity in over 18 months

Developed by
Equillium
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Indications
Alopecia areata
Last public activity
September 2022
Record confidence
Medium

Why it matters

IL-15 is the cytokine the JAK inhibitors are ultimately interrupting in alopecia areata, and BNZ-1 targets it directly along with IL-2 and IL-9. Blocking the cytokine rather than the kinase downstream of it is a narrower intervention than a JAK inhibitor — which is the argument for better tolerability, and the risk of less effect.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT03532958 — Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT03532958Phase 2WITHDRAWN

    Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

    Equillium · October 2021

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources